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generated in situ by the NADPH oxidase
and granule proteins delivered by phago-
lysosome fusion create an environment
extremely inhospitable to ingested mi-
crobes. Among the toxic agents gener-
ated areHOCl, bleach, the oxidation prod-
uct of H2O2, and the granule protein
myeloperoxidase (MPO) in the presence
of chloride. The products of the NADPH
oxidase oxidatively deactivate the AIP
molecule (Rothfork et al., 2004) but also
oxidize lipoproteins and thus potentially
compromise interactions between ApoB
and AIP. Although acetylated LDL still
blocks quorum sensing by AIP, the MPO-
H2O2-chloride system supports a broad
array of posttranslational changes, includ-
ing tyrosinechlorination, oxidationof thiol-
containing targets, selective modification
of apoA-1 in high-density lipoprotein
(HDL), oxidation of tryptophan residues,
and oxidation of phosphoryl serine, etha-
nolamine, and choline. Given the potency
of species generated in the neutrophil
phagosome, the contribution of ApoB-
AIP interactions to quorum sensing of
ingested S. aureusmerits further study.
In summary, S. aureus employs quorum
sensing as critical regulatory mechanism
to shift the balance from a colonizing to
an invasive state. The triggering of this
switch could be detrimental to the host,
potentially leading to the evolution of in-
nate antagonistic mechanisms to repress
the response. Peterson et al. indicate that
ApoB may provide one mechanism that
operates through sequestering of the
AIP signal. Interestingly, ApoB also binds
to AIP structures composed of different
amino acids produced by other S. aureus
strains, but not linearized versions of AIP
peptides, suggesting that ApoB may
have general affinity for the cyclic moiety
of AIP molecules. Considering other
Gram-positive pathogens encode genes
to produce similar AIP structures (Lyon
and Novick, 2004), ApoB could serve as a
general host defense mechanism against
cyclic peptide based quorum sensing.
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Cure of rodentmalaria with the biocide triclosan highlighted the enzyme FabI as an antimalarial drug target. In
this issue ofCell Host &Microbe, Yu et al. (2008) show that FabI is not the principle target of triclosan yet plays
an important role specifically in malaria liver stage development.The malaria parasite Plasmodium falcipa-
rum infects two types of human host cells
during distinct stages of its life cycle. After
the bite of an infected Anopheles mos-
quito, malaria parasites infect hepato-
cytes, where they undergo a period of
explosive growth, multiplying 10,000-
fold. These parasites are then released
to the blood stream, where they invade
red blood cells and begin the cyclic eryth-
rocytic stage that is the cause of malariamorbidity andmortality. Parasite develop-
ment within these two very different cell
typeswhile in the human host leads to fas-
cinating biological questions about which
nutrients are scavenged from the host,
which are synthesized by the parasite,
and how these processes vary throughout
the complex parasite life cycle.
The acquisition of fatty acids by erythro-
cytic-stage parasites has been of great
recent interest to the field. Erythrocytic-Cell Host & Microbe 4, Dstage P. falciparum has long been known
to scavenge fatty acids from the host,
and these lipids are used in multiple pro-
cesses, including phospholipid and tria-
cylglycerol synthesis (Vial et al., 1982).
P. falciparum was believed to be an obli-
gate scavenger of fatty acids until a type
II fatty acid synthase (FAS II) was identified
in the genome, showing that malaria is
capable of de novo fatty acid synthesis
(Gardner et al., 1998; Waller et al., 1998).ecember 11, 2008 ª2008 Elsevier Inc. 509
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micro-organisms and plants and are the
targets of several antimicrobial agents that
do not inhibit the type I FAS found inmam-
mals (reviewed in Heath et al., 2001). One
of these agents, the antimicrobial biocide
triclosan, was reported to cure mice
infected with the rodent malaria Plasmo-
dium berghei (Surolia and Surolia, 2001).
Additional experiments showed that tri-
closan inhibits the growth of P. falciparum
in culture and inhibits the incorporation
of [14C]-acetate into parasite fatty acids
(Surolia and Surolia, 2001). Based on
these results, the malaria FAS II enzymes,
particularly the enzyme inhibited by
triclosan (PfFabI), became the focus of
intense drug discovery efforts (Lu et al.,
2005).
In this issue of Cell Host & Microbe, Yu
and colleagues show that PfFabI is not
the principle target of triclosan in malaria
and that the FAS II is not essential for
blood-stage parasite survival but plays
an important role in liver-stage develop-
ment (Yu et al., 2008). Initial doubts about
the role of the FAS II in the blood stages of
malaria arose during a drug discovery
project. In aneffort todevelopmorepotent
PfFabI inhibitors, Yu and colleagues de-
signed 80 triclosan analogs based on the
PfFabI crystal structure and evaluated
these compounds for their ability to inhibit
PfFabI enzymatic activity and the growth
of P. falciparum in red blood cell culture.
Surprisingly, there was little correlation
between inhibition of enzyme activity and
parasite growth. In fact, the compounds
that were most potent in culture were
poor inhibitors of the enzyme, suggesting
that PfFabI may not be the target of triclo-
san and its analogs. The relationship
between PfFabI and triclosan was further
investigated by analyzing triclosan sus-
ceptibility in P. falciparum cell lines ex-
pressing a second copy of the pffabI
gene under control of a strong promoter.
Overexpression of PfFabI did not alter
the sensitivity of theparasites for triclosan,
even when a triclosan-resistant PfFabI
mutant was expressed. These results
demonstrated that, even though triclosan
is a potent inhibitor of PfFabI activity, it
does not kill parasites by inhibiting PfFabI,
as was previously believed.
Two key questions emerged from these
results: Are triclosan and its analogs
effective antimalarials? Is the type II FAS
important for parasite survival? Triclosan510 Cell Host & Microbe 4, December 11, 20is a safe and ubiquitous antimicrobial
found inmany consumer goods and could
represent a class of effective antimalarial
compounds. Yu and colleagues adminis-
tered triclosan to mice infected with the
rodent malaria P. berghei, which typically
kills mice over the course of 8–10 days. At
the maximum tolerable dose of triclosan,
they observed 30%–50% survival after
30 days; this is in contrast to the complete
clearance of parasites after 8 days and
100% survival previously reported (Suro-
lia and Surolia, 2001). Based on these
studies, it is evident that triclosan has
in vivo antimalarial activity; however, this
activity is not robust enough to warrant
pursing triclosan itself as a therapeutic.
Among the triclosan analogs tested in
in vitro culture, several were more potent
inhibitors of P. falciparum growth than tri-
closan. A structure activity analysis of
these compounds indicates that substi-
tution of one of the ring chlorine atoms
with other substituents tends to result in
increased potency. Although not investi-
gated here, analysis of the antimalarial
properties of these compounds in the
in vivo rodent malaria model would pro-
vide insight into the usefulness of triclosan
analogs against malaria blood stages and
may provide information about potential
targets of triclosan activity.
The discovery that inhibition of PfFabI is
not the mode of action of triclosan in ma-
laria raised the possibility that this enzyme
is not essential for parasite growth during
the blood stages. Yu and colleagues
probed this question by generating genet-
ically modified strains ofP. falciparum and
P. berghei, which do not produce FabI.
Results from the two malaria species pro-
vide complementary information. Studies
in P. falciparum provide information about
the human pathogen but are restricted to
in vitro blood-stage culture. In contrast,
the effects of P. berghei gene deletions
can be studied in vivo, providing informa-
tion about all stages of the parasite life
cycle, albeit in a murine host. Disruption
of the P. falciparum pffabI gene (PfDfabI)
and deletion of the orthologous P. berghei
pbfabI (PbDfabI) did not alter blood-stage
growth, demonstrating that FabI is not
essential for this stage. The genomes of
P. falciparum and P. berghei do not ap-
pear to encode other reductase enzymes
that could complement the loss of FabI.
Thus, the absence of growth phenotypes
in these cell lines indicates that type II08 ª2008 Elsevier Inc.fatty acid biosynthesis is not vital to the
erythrocytic stages of malaria parasites.
Despite disruption of de novo fatty acid
biosynthesis, the PfDfabI and PbDfabI
parasite strains produce fatty acids la-
beled with [14C]-acetate. These are likely
the products of fatty acid elongase (ELO)
enzymes encoded in both genomes.
Preliminary studies demonstrate that
Toxoplasma gondii orthologs of the Plas-
modium falciparum ELO genes are
enzymatically active and complement
ELO-deficient strains of Trypanosoma
brucei (S. Subramaniam, D. Shanmugam,
J. Stephens, P. Englund, and D.S. Roos,
personal communication). In light of these
new data, previous work showing de-
creased production of labeled fatty acids
after treatment with triclosan can now
be reinterpreted. In these experiments,
it is likely that triclosan was ultimately
affecting fatty acid elongation rather than
type II fatty acid biosynthesis.
After demonstrating that FabI is not im-
portant for erythrocytic-stage growth, Yu
and colleagues explored other stages of
malaria development. The PbDfabI strain
formed gametocytes and progressed
normally through the mosquito stages of
the life cycle; however, mice infected
with PbDfabI sporozoites were less likely
to develop blood-stage malaria than
controls. Among the PbDfabI infections
that developed into blood-stage malaria,
patency was delayed by several days, in-
dicating attenuated liver-stage develop-
ment (Figure 1). Careful analysis of liver-
stage development showed that PbDfabI
parasites successfully invade hepato-
cytes and begin to develop normally;
however, abnormalities appear late in
the liver stage. In particular, a protein typ-
ically found on the surface of developing
merozoites is absent in the PbDfabI strain,
indicating that there is a defect in the for-
mation of merozoites competent to infect
red blood cells. These results comple-
ment recent microarray data showing
that FAS II genes are upregulated in the
parasite liver stages (Tarun et al., 2008)
and indicate that the FAS II plays a critical
role in this part of the parasite life cycle.
The findings of Yu and colleagues prompt
revision of the paradigm that erythrocytic-
stage parasites rely on de novo fatty acid
biosynthesis to supplement fatty acid
scavenging. Instead, it appears that the
FAS II is not essential for the blood stages
but plays a vital role in liver-stage
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Previewsdevelopment. Thiswork adds to agrowing
body of evidence that type II fatty acid
biosynthesis is central to normal liver-
stage development and may be exploited
for malaria prophylaxis.
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Figure 1. Deletion of the Fatty Acid Synthesis Gene pbfabI in P. Berghei Causes Attenuation of Liver-Stage Development
(Top) Mice infected with wild-type P. berghei sporozoites develop patent blood-stage infection within 5 days.
(Bottom) Infection with PbDfabI sporozoites results in attenuated liver-stage development (gray images), which can block progression to the blood stages.
Blood-stage infection, if it occurs, is typically delayed and does not become patent until around 9 days after sporozoite invasion.Cell Host & Microbe 4, December 11, 2008 ª2008 Elsevier Inc. 511
